Vessix veteran becomes JenaValve chairman
This article was originally published in Clinica
Executive Summary
Transcatheter aortic valve implantation (TAVI) device contender JenaValve Technology (Wilmington, Delaware and Munich, Germany) has appointed Raymond Cohen chairman. Mr Cohen was CEO of renal denervation specialist Vessix Vascular, a position he held since 2010; Boston Scientific acquired Vessix in a deal worth up to $425 million last year (www.clinica.co.uk, 9 November 2012). He was also chairman and CEO of automatic external defibrillator firm Cardiac Science, between 1997 and 2006. Mr Cohen currently serves on the board of several other firms including BioLife Solutions, which manufactures biopreservation media for human cells and tissues, and LoneStar Heart, a developer of biomaterials for the treatment of congestive heart failure. He replaces previous JenaValve chairman Michael Dormer, who will take up an advisory role.